Macular Edema - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 63
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MD75D55BE2DEN
Leaflet:

Download PDF Leaflet

Macular Edema - Pipeline Review, H2 2016
Macular Edema - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema – Pipeline Review, H2 2016, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 2, 9, 1 and 1 respectively.Macular Edema.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Macular Edema Overview
Therapeutics Development
Pipeline Products for Macular Edema - Overview
Macular Edema - Therapeutics under Development by Companies
Macular Edema - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Macular Edema - Products under Development by Companies
Macular Edema - Companies Involved in Therapeutics Development
ActiveSite Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc.
Chong Kun Dang Pharmaceutical Corp.
Clearside BioMedical, Inc.
Coherus BioSciences, Inc.
Mabion SA
Pfizer Inc.
Precision Ocular Ltd
Promedior, Inc.
Taiwan Liposome Company, Ltd.
Valeant Pharmaceuticals International, Inc.
Xbrane Biopharma AB
Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aflibercept + triamcinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASPPDC-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLO-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone sodium phosphate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HO-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 63

LIST OF TABLES

Number of Products under Development for Macular Edema, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2016
Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
Macular Edema - Pipeline by Clearside BioMedical, Inc., H2 2016
Macular Edema - Pipeline by Coherus BioSciences, Inc., H2 2016
Macular Edema - Pipeline by Mabion SA, H2 2016
Macular Edema - Pipeline by Pfizer Inc., H2 2016
Macular Edema - Pipeline by Precision Ocular Ltd, H2 2016
Macular Edema - Pipeline by Promedior, Inc., H2 2016
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Macular Edema - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Macular Edema - Dormant Projects, H2 2016
Macular Edema - Discontinued Products, H2 2016 57

LIST OF FIGURES

Number of Products under Development for Macular Edema, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Diabetic Macular Edema - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 195 pages

Ask Your Question

Macular Edema - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: